Gilead's HIV franchise looks secure as 'son of Viread' impresses in PhIII
This article was originally published in Scrip
Executive Summary
Two Phase III trials of Gilead Sciences' once-daily tablet containing its next-generation Viread product, tenofovir alafenamide (TAF), have met their primary objectives. The data are expected to help Gilead fight off generic competition to its hugely successful HIV franchise.
You may also be interested in...
Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?
Company hopes TAF-based combo incorporating integrase inhibitor bictegravir can help it compete with ViiV, but beyond that pipeline holds only early-stage and smaller opportunities in HIV. Analysts call on Gilead to use its cash stockpile to find its next R&D focus.
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.